# Northwest Natural Gas Company — Pipeline Safety Interpretation - **operation:** document - **citation:** PI-95-011 - **title:** Northwest Natural Gas Company — Pipeline Safety Interpretation - **source type:** guidance - **agency:** Pipeline and Hazardous Materials Safety Administration - **status:** guidance - **official:** true - **published on:** 1995-05-08 - **effective on:** Not available - **summary:** PI-95-011 response to Northwest Natural Gas Company concerning 199.3. - **machine formats:** - **json:** https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011.json - **markdown:** https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011.md - **app url:** https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011 - **source url:** https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/Pipeline/1995/PI95011.pdf **body:** <<>> U.S. Department 400 Seventh Street, SW of Transportation Washington, DC 20590 Research and Special Programs Administration (No Date) Ms. Deborah Jacobsen, R.N. Northwest Natural Gas Company 220 N.W. Second Avenue Portland, Oregon 97209-3991 Dear Ms. Jacobsen: This is in response to your correspondence dated May 8, 1995, pertaining to an employee who is using a prescription drug. The Research and Special Programs Administration (RSPA) does not have any prohibitions in its drug rule against an employee’ s use of prescription drugs. Therefore, you may not test an individual for prescription drugs under the authority of the Research and Special Programs Administration. Thank you for your inquiry. 366-6199. If you need additional information please contact Catrina M. Pavlik on (202) Sincerely, G. Tom Fortner Director for Compliance and State Programs Office of Pipeline Safety 95-05-08.doc 199.3 40.21 - **truncated:** false - **body characters:** 922